Your browser doesn't support javascript.
loading
Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis.
Ang, Song Peng; Chia, Jia Ee; Valladares, Carlos; Patel, Shreya; Gewirtz, Daniel; Iglesias, Jose.
Afiliación
  • Ang SP; Department of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.
  • Chia JE; Department of Internal Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA.
  • Valladares C; Department of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.
  • Patel S; Touro College of Osteopathic Medicine, New York, NY 10027, USA.
  • Gewirtz D; Department of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.
  • Iglesias J; Department of Medicine, Rutgers Health Community Medical Center, Toms River, NJ 08755, USA.
Biomedicines ; 12(7)2024 Jun 25.
Article en En | MEDLINE | ID: mdl-39061988
ABSTRACT

INTRODUCTION:

Proton pump inhibitors (PPIs) are among the most commonly prescribed medications. Recently, PPI use has been linked to the development of chronic kidney disease (CKD) and cardiovascular events. Our study aimed to investigate the relationship between PPI use and the incidence of chronic kidney disease using a systematic review and meta-analysis.

METHODS:

We performed a comprehensive literature search in PubMed, Embase, and Cochrane databases from their inception until March 2024 for relevant studies. We compared outcomes between patients using PPIs, those not using PPIs, and those using histamine-2 receptor antagonists (H2RAs). Endpoints were pooled using the DerSimonian-and-Laird random-effects model as the hazard ratio (HR) with 95% confidence intervals (CIs).

RESULTS:

Our analysis included twelve studies with a total of 700,125 participants (286,488 on PPIs, 373,848 not on PPIs, and 39,789 on H2RAs), with follow-up periods ranging from three months to 14 years. The current meta-analysis revealed that PPI use is associated with a statistically significant increased risk of incident CKD (HR 1.26, 95% CI 1.16-1.38, p < 0.001) compared with non-users. Moreover, the risk of incident CKD is significantly higher in patients with PPI use compared to H2RA use (HR 1.34, 95% CI 1.13-1.59, p < 0.001). The results remained unchanged in terms of magnitude and direction after a leave-one-out analysis for both outcomes.

CONCLUSIONS:

Our multifaceted analysis showed that PPI use was associated with a higher incidence of CKD when compared to non-PPI use and H2RA use, respectively. These findings advocate for heightened vigilance and judicious use of long-term PPIs. Further large prospective longitudinal studies are warranted to validate these observations.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Biomedicines Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza